PMA filing review procedures to be clarified via "blue book" changes, ODE's Alpert says.
This article was originally published in The Gray Sheet
Executive Summary
PMA FILING REVIEW CONSISTENCY TO BE IMPROVED through training and revisions to FDA's "blue book" memo on filing procedures for premarket approval applications, Susan Alpert, director of the Office of Device Evaluation in FDA's Center for Devices and Radiological Health, said Nov. 8 at a meeting on in vitro diagnostics held by the Health Industry Manufacturers Association in Arlington, Virginia. Noting the agency's effort to "retrain" reviewers "on how to file" PMAs, Alpert said ODE is "reassessing what our blue book memorandum, our SOP, says about filing."
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.